Detailed Narrative
FY25 Financial Performance Overview
Accent Microcell reported a robust financial performance for FY25, with revenue from operations increasing by 8% year-over-year to ₹265 crores. The company's PAT also saw a significant rise of 10% YoY, reaching ₹33 crores. EBITDA grew by 12% YoY, contributing to a consolidated EBITDA margin of 15-16% and a PAT margin of 12-13% for the fiscal year. This growth was achieved despite a significant drop in borrowings compared to the previous year.
Unit 3 Expansion and Product Portfolio Diversification
The company is actively pursuing its Unit 3 expansion, with Phase 1 commercial production anticipated to begin in September-October 2025. This phase will introduce three new premium excipient products (CCS, CMC, SSG) and is expected to generate ₹70 crores in revenue during H2 FY25 from confirmed orders. The peak revenue potential for Phase 1 is estimated at ₹150-160 crores. Phase 2 of Unit 3, focusing on MCC production, is projected to be commercialized around June 2026, with a peak revenue potential of ₹220-250 crores on a standalone basis. The combined Unit 3 is expected to contribute ₹400-425 crores to revenue in FY26 (considering Phase 1 only).
Margin Improvement and Export Focus
Management expects significant margin improvement with the commercialization of Unit 3, targeting roughly 25% on a bottom-line basis for premium-range products. The premium-range component from Unit 3 is projected to constitute 25-30% of the total revenue from that unit. The company also aims to increase its export ratio compared to the reported period, as export margins are generally higher, particularly for sales to the U.S. market. This strategic shift towards premium products and exports is expected to enhance overall blended margins.
Capital Expenditure and Funding Strategy
The total capex for Unit 3 Phase 1 is estimated at ₹55 crores, which will be reflected in the next financials. An additional ₹55-60 crores is planned for Unit 3 Phase 2. The company has received in-principle approval for a rights issue of up to ₹940 crores to fund this expansion, with the balance of the project cost to be covered by internal accruals. The asset-turnover ratio for Unit 3 (Phase 1 + Phase 2) is projected to be between 4.5 to 5 times once fully ramped up, indicating efficient capital deployment.
Raw Material Sourcing and Price Management
Accent Microcell sources its wood pulp, a primary raw material, from diverse international suppliers including South Africa, USA, Canada, Sweden, and Indonesia. While the COVID era saw abnormal fluctuations, prices have returned to pre-COVID levels. Management does not foresee major price changes and has a system in place to manage volatility, including fixed purchase prices for one quarter and offsetting increases through finished goods sales in the export market.
Working Capital and Related Party Transactions
The company experienced a temporary increase in working capital levels due to offering liberal payment terms to new Indian MNC customers. However, management expects no additional working capital requirements for Unit 1 and Unit 2 in the future. Related party transactions have been substantially reduced in H2 FY25 and are expected to become negligible as the company focuses on in-house activities.